Abstract Despite the promising anticancer properties of PARP-1 inhibitors, their clinical use is hindered by side effects. It is crucial to explore new structural variants of these inhibitors to increase efficacy and minimize side effects, enhancing their clinical viability and therapeutic scope. In this study, we developed a virtual screening workflow that synergistically integrates Transfoxmol, KarmaDock, and PLANET with AutoDock Vina's capabilities. Through structural clustering, we identified ten potential PARP-1 inhibitors. Additionally, through molecular dynamics simulations and MM/PBSA, we elucidated the binding modes of compounds 1, 3, 6, and 9 with PARP-1, providing insights for drug development.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: